{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:06:56Z","timestamp":1792206416524,"version":"4.4.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is an ultrarare thrombotic disease caused by autoantibody-induced ADAMTS13 deficiency. Open ADAMST13 conformation, induced by autoantibodies, was identified as a novel biomarker for iTTP. Determining immunoprofiles in patients with iTTP has been shown to guide the development of novel targeted therapies. However, these studies were done in mainly Caucasian iTTP cohorts. To validate those findings across other ethnic cohorts, we investigated 195 acute TTP plasma samples from the Japanese iTTP registry. Seventy-six of the 195 samples had detectable ADAMTS13 antigen levels, of which 94.7% were shown to have an open ADAMTS13 conformation. A positive correlation was observed between ADAMTS13 inhibitor titers (a diagnostic parameter in Japan) and anti-ADAMTS13 immunoglobulin G autoantibody titers. Studying anti-M, anti-DT, anti-CS, anti-T2-T5, anti-T6-T8, anti\u2013CUB1-2 autoantibodies and the corresponding immunoprofile showed that 73% of the patients had anti-CS autoantibodies and 25.8% had anti-M autoantibodies, with the latter being higher than in Caucasians. Stratifying patients according to their immunoprofiles revealed that the profile with only anti-CS autoantibodies was the most common immunoprofile similar to that in Caucasians (28.9%). Although this profile did not affect the 1-year TTP-related mortality rate, patients with autoantibodies against all 6 ADAMTS13 fragments had a higher risk for TTP-related death than other patients (P\u00a0= .02). We here validated open ADAMTS13 as a novel biomarker for acute iTTP and determined the dominant immunoprofiling in the Japanese cohort, contributing to setting up the diagnosis and managing guidelines across different ethnic cohorts and developing ADAMTS13 variants that do not bind to the anti-CS autoantibodies.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008885","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T13:47:39Z","timestamp":1666964859000},"page":"131-140","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0523-7931","authenticated-orcid":false,"given":"Kazuya","family":"Sakai","sequence":"first","affiliation":[{"name":"1Laboratory for Thrombosis Research, IRF Life Sciences, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium"},{"name":"2Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7243-3126","authenticated-orcid":false,"given":"Masanori","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"2Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6929-9229","authenticated-orcid":false,"given":"Laure","family":"De Waele","sequence":"additional","affiliation":[{"name":"1Laboratory for Thrombosis Research, IRF Life Sciences, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6760-9863","authenticated-orcid":false,"given":"Charlotte","family":"Dekimpe","sequence":"additional","affiliation":[{"name":"1Laboratory for Thrombosis Research, IRF Life Sciences, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0913-2475","authenticated-orcid":false,"given":"Eriko","family":"Hamada","sequence":"additional","affiliation":[{"name":"2Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5768-1025","authenticated-orcid":false,"given":"Masayuki","family":"Kubo","sequence":"additional","affiliation":[{"name":"2Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6380-6349","authenticated-orcid":false,"given":"Claudia","family":"Tersteeg","sequence":"additional","affiliation":[{"name":"1Laboratory for Thrombosis Research, IRF Life Sciences, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1807-5882","authenticated-orcid":false,"given":"Simon F.","family":"De Meyer","sequence":"additional","affiliation":[{"name":"1Laboratory for Thrombosis Research, IRF Life Sciences, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-8277","authenticated-orcid":false,"given":"Karen","family":"Vanhoorelbeke","sequence":"additional","affiliation":[{"name":"1Laboratory for Thrombosis Research, IRF Life Sciences, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2023011218095915600_bib1","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood-2017-04-636431","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura","volume":"130","author":"Sadler","year":"2017","journal-title":"Blood"},{"key":"2023011218095915600_bib2","first-page":"1","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Prim"},{"issue":"21","key":"2023011218095915600_bib3","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2023011218095915600_bib4","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2023011218095915600_bib5","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1182\/blood.V91.8.2839.2839_2839_2846","article-title":"Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura","volume":"91","author":"Furlan","year":"1998","journal-title":"Blood"},{"issue":"14","key":"2023011218095915600_bib6","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2023011218095915600_bib7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2023011218095915600_bib8","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"7","key":"2023011218095915600_bib9","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A\u00a0phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2023011218095915600_bib10","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/bloodadvances.2019031039","article-title":"Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura","volume":"3","author":"Sun","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"2023011218095915600_bib11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/jth.13922","article-title":"An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura","volume":"16","author":"Roose","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2023011218095915600_bib12","first-page":"353","article-title":"Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura","volume":"136","author":"Roose","year":"2020","journal-title":"Blood"},{"issue":"17","key":"2023011218095915600_bib13","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1182\/bloodadvances.2020004172","article-title":"Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura","volume":"5","author":"Kangro","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"2023011218095915600_bib14","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.019299","article-title":"Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura","volume":"95","author":"Zheng","year":"2010","journal-title":"Haematologica"},{"issue":"12","key":"2023011218095915600_bib15","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1182\/blood-2003-12-4165","article-title":"Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura","volume":"103","author":"Klaus","year":"2004","journal-title":"Blood"},{"issue":"16","key":"2023011218095915600_bib16","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1182\/blood-2011-12-399501","article-title":"Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura","volume":"119","author":"Jian","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2023011218095915600_bib17","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.3324\/haematol.2019.226068","article-title":"Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura","volume":"105","author":"Gra\u00e7a","year":"2020","journal-title":"Haematologica"},{"key":"2023011218095915600_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.01646","article-title":"Concentration and subclass distribution of anti-ADAMTS13 IgG autoantibodies in different stages of acquired idiopathic thrombotic thrombocytopenic purpura","volume":"9","author":"Sinkovits","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"2023011218095915600_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0033029","article-title":"Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan","volume":"7","author":"Matsumoto","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"2023011218095915600_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-017-2264-7","article-title":"Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan","volume":"106","author":"Matsumoto","year":"2017","journal-title":"Int J Hematol"},{"issue":"8","key":"2023011218095915600_bib21","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/j.1537-2995.2006.00914.x","article-title":"Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity","volume":"46","author":"Kato","year":"2006","journal-title":"Transfusion"},{"issue":"4","key":"2023011218095915600_bib22","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/jth.14747","article-title":"Anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura do not hamper ELISA-based quantification of ADAMTS13 antigen","volume":"18","author":"Dekimpe","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"9","key":"2023011218095915600_bib23","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1111\/jth.15297","article-title":"Determination of anti-ADAMTS-13 autoantibody titers in ELISA: influence of ADAMTS-13 presentation and autoantibody detection","volume":"19","author":"Dekimpe","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"2023011218095915600_bib24","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/rth2.12379","article-title":"Generation and validation of small ADAMTS13 fragments for epitope mapping of anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura","volume":"4","author":"Kangro","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"10","key":"2023011218095915600_bib25","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"10","key":"2023011218095915600_bib26","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1111\/jth.15009","article-title":"Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"2023011218095915600_bib27","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023011218095915600_bib28","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2004-11-4490","article-title":"ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases","volume":"106","author":"Rieger","year":"2005","journal-title":"Blood"},{"issue":"10","key":"2023011218095915600_bib29","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/j.1538-7836.2009.03568.x","article-title":"IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura","volume":"7","author":"Ferrari","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2023011218095915600_bib30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1538-7836.2008.03250.x","article-title":"VH1-69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura","volume":"7","author":"Pos","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"issue":"10","key":"2023011218095915600_bib31","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1055\/s-0038-1669459","article-title":"Anti-ADAMTS13 autoantibodies against cryptic epitopes in immune-mediated thrombotic thrombocytopenic purpura","volume":"118","author":"Roose","year":"2018","journal-title":"Thromb Haemost"},{"issue":"7","key":"2023011218095915600_bib32","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/trf.13584","article-title":"ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in\u00a0vitro","volume":"56","author":"Ostertag","year":"2016","journal-title":"Transfusion"},{"key":"2023011218095915600_bib33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2019.10.012","article-title":"Acquired von Willebrand syndrome in patients on long-term left ventricular assist device support: results of a Belgian center","volume":"184","author":"Deconinck","year":"2019","journal-title":"Thromb Res"},{"issue":"2","key":"2023011218095915600_bib34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1538-7836.2009.03692.x","article-title":"Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: evidence for an immunogenetic link","volume":"8","author":"Scully","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"2023011218095915600_bib35","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1538-7836.2010.03772.x","article-title":"HLA-DRB1\u221711: a strong risk factor for acquired severe ADAMTS13 deficiency-related idiopathic thrombotic thrombocytopenic purpura in Caucasians","volume":"8","author":"Coppo","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"2023011218095915600_bib36","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00277-011-1384-z","article-title":"The role of human leukocyte antigens as predisposing and\/or protective factors in patients with idiopathic thrombotic thrombocytopenic purpura","volume":"91","author":"John","year":"2012","journal-title":"Ann Hematol"},{"issue":"26","key":"2023011218095915600_bib37","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood.2020005395","article-title":"HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR","volume":"135","author":"Sakai","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2023011218095915600_bib38","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1191\/0961203306lu2331oa","article-title":"Anti-glycan antibodies as biomarkers for diagnosis and prognosis","volume":"15","author":"Dotan","year":"2006","journal-title":"Lupus"},{"issue":"13","key":"2023011218095915600_bib39","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1177\/0961203311417033","article-title":"Antinucleosome antibodies as a potential biomarker for the evaluation of renal pathological activity in patients with proliferative lupus nephritis","volume":"20","author":"Hung","year":"2011","journal-title":"Lupus"},{"issue":"9","key":"2023011218095915600_bib40","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/jnnp-2012-302705","article-title":"Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis","volume":"83","author":"Masuda","year":"2012","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"8","key":"2023011218095915600_bib41","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ebiom.2015.06.007","article-title":"Pathogenicity of anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura","volume":"2","author":"Thomas","year":"2015","journal-title":"EBioMedicine"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/1\/131\/2028873\/blooda_adv-2022-008885-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/1\/131\/2028873\/blooda_adv-2022-008885-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T13:11:53Z","timestamp":1673529113000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/1\/131\/486939\/ADAMTS13-conformation-and-immunoprofiles-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008885","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]}}}